In this way, specific therapeutic agents, such as trastuzumab [11,12], pertuzumab [13,14], and lapatinib [15,16,17], have been developed, representing an extremely important tool in the precision era medicine that is able to significantly improve the life expectancy of HER2-positive BC patients [18]. Here, ERBB2 is linked to breast cancer.